Erytech Pharma opens U.S. enrollment in TRYbeCA1 Phase 3 clinical trial

Erytech Pharma announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer. TRYbeCA1 was opened for patient enrollment in the United States last week, and the first of a planned total of 30 U.S. sites was activated. This marks an important step to expand the trial to approximately 100 sites across several European countries and the U.S. The manufacturing of eryaspase for the patients to be treated in the U.S. will take place at the newly established manufacturing facility in Princeton, N.J. Separately, on October 29, further to its review of the safety data of the first 150 enrolled and treated patients in the TRYbeCA1 trial, the Independent Data Monitoring Committee, or IDMC, identified no safety issues and recommended the trial to continue as planned.